People have experienced vision improvements with BEOVU
BEOVU was assessed in 368 people with diabetic macular edema (DME) across 2 clinical studies. Both studies measured the mean change in best corrected visual acuity (ability to read letters on an eye chart) at Year 1.
With BEOVU, it's possible to maintain vision
Both studies also measured the percentage of people who maintained vision at Year 1.
Remember, staying consistent with your appointments can help maintain your vision.
Treatment every 3 months is possible with BEOVU
For the first 5 treatments, BEOVU is given every 6 weeks.* (The recommended starting dose for other anti-VEGFs is every 4 weeks according to their approved dose for DME.) BEOVU is then given once every 2 or 3 months depending on how well your eye responds to treatment.
Talk to your doctor about what treatment schedule is best for you.
*The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every 6 weeks (approximately every 39-45 days) for the first 5 doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks.
How BEOVU works
What is VEGF?
VEGF is a protein responsible for producing new blood vessels. DME can cause VEGF to become overactive, which drives the growth of new blood vessels that can leak fluid into the macula.
Download our patient brochure for more guidance on DME, including how to start the conversation with your doctor.